These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12819817)

  • 1. Toxicogenomics takes center stage.
    Lehmann J
    Drug News Perspect; 2003 Apr; 16(3):183-6. PubMed ID: 12819817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of toxicogenomics.
    Hamadeh HK; Amin RP; Paules RS; Afshari CA
    Curr Issues Mol Biol; 2002 Apr; 4(2):45-56. PubMed ID: 11931569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a best strategy for drug discovery?
    Warne P; Page C
    Drug News Perspect; 2003 Apr; 16(3):177-82. PubMed ID: 12819816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicogenomics in drug discovery and development -- making an impact.
    Wills Q; Mitchell C
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():33-7. PubMed ID: 19807202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of toxicogenomics to drug development.
    Lakkis MM; DeCristofaro MF; Ahr HJ; Mansfield TA
    Expert Rev Mol Diagn; 2002 Jul; 2(4):337-45. PubMed ID: 12138498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of pharmacoproteomics in the development of personalized medicine.
    Jain KK
    Pharmacogenomics; 2004 Apr; 5(3):331-6. PubMed ID: 15102547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
    Kramer JA; Kolaja KL
    Expert Opin Drug Saf; 2002 Sep; 1(3):275-86. PubMed ID: 12904143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective.
    Vahle JL; Anderson U; Blomme EAG; Hoflack JC; Stiehl DP
    Regul Toxicol Pharmacol; 2018 Jul; 96():18-29. PubMed ID: 29679677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics: New Developments in Target Discovery.
    Nagy JM; Brown KA
    Drug News Perspect; 2002 Nov; 15(9):601-603. PubMed ID: 12677201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental biology's impact on drug development.
    Cohen CM; Platika D; Scangos G; Kilian P
    Nat Biotechnol; 1998 Jul; 16(7):628-31. PubMed ID: 9661194
    [No Abstract]   [Full Text] [Related]  

  • 11. Application of toxicogenomics in drug development.
    Gant TW
    Drug News Perspect; 2003 May; 16(4):217-21. PubMed ID: 12942151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics: development issues and solutions for safe and effective medicines.
    Arnold HP; McHale D
    Pharmacogenomics; 2006 Mar; 7(2):149-55. PubMed ID: 16515393
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenetics and drug metabolism.
    Ball S; Borman N
    Nat Biotechnol; 1997 Oct; 15(10):925-6. PubMed ID: 9335033
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database.
    Ganter B; Snyder RD; Halbert DN; Lee MD
    Pharmacogenomics; 2006 Oct; 7(7):1025-44. PubMed ID: 17054413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S
    Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protozoan genomics for drug discovery.
    Chaudhary K; Roos DS
    Nat Biotechnol; 2005 Sep; 23(9):1089-91. PubMed ID: 16151400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Toxicogenomics--a new paradigm of toxicology and birth of reverse toxicology].
    Hirabayashi Y; Inoue T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2002; (120):39-52. PubMed ID: 12638183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel technology and the development of pharmacogenetics within the pharmaceutical industry.
    Gibson N; Jawaid A; March R
    Pharmacogenomics; 2005 Jun; 6(4):339-56. PubMed ID: 16004553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profits.
    Kerb R; Brinkmann U
    Pharmacogenomics; 2001 Aug; 2(3):303-5. PubMed ID: 11939136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary roles for toxicologic pathology and mathematics in toxicogenomics, with special reference to data interpretation and oscillatory dynamics.
    Morgan KT; Pino M; Crosby LM; Wang M; Elston TC; Jayyosi Z; Bonnefoi M; Boorman G
    Toxicol Pathol; 2004; 32 Suppl 1():13-25. PubMed ID: 15209399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.